Doseology Sciences Inc. Strengthens Portfolio with Acquisition

Author: Evelyn Baker Updated: 08-27-2025 07:33 AM

Doseology Completes Strategic Acquisition

Doseology Sciences Inc. (CSE: MOOD, OTC: DOSEF, FSE: VU) is thrilled to announce an important milestone in its mission to be a leader in precision-formulated oral stimulants. The company has successfully closed the acquisition of the "Feed That Brain" division from Joseph Mimran & Associates Inc., marking a significant advancement for Doseology.

Details of the Acquisition

As part of the acquisition agreement, Doseology has issued 175,000 common shares at a deemed price of $1.00 per share. This transaction fulfills the first payment required under the asset purchase and sale agreement between Doseology and the Vendor. The shares distributed to the Vendor will be subject to a four-month hold period, in compliance with existing Canadian securities laws.

Expanding Product Offerings

This acquisition allows Doseology to bolster its product portfolio, particularly in the realm of cognitive enhancement and stimulation. The "Feed That Brain" product line is known for harnessing unique ingredients aimed at improving energy, focus, and overall cognitive performance. By integrating this division, Doseology will be positioned to offer enhanced solutions to its customers.

Innovation in Cognitive Performance

At Doseology, innovation is at the forefront of its operations. The company focuses on developing advanced oral stimulant formulas backed by rigorous scientific research. The newly acquired products align perfectly with Doseology's existing mission to create next-generation performance solutions that empower individuals to achieve peak cognitive abilities.

Leadership Vision

"We are excited to welcome the Feed That Brain team into the Doseology family," said Chris Jackson, CEO of Doseology Sciences Inc. "This acquisition is a strategic move that enhances our capabilities and offerings in cognitive enhancement products, enabling us to serve our clients better and drive further innovation in the industry."

Commitment to Excellence

Doseology's commitment to developing premium-quality cognitive products remains unwavering. With this acquisition, the company plans to leverage existing technologies and research to enhance product formulations that support mental acuity and overall cognitive health.

Looking to the Future

As Doseology Sciences Inc. continues to expand its reach through strategic acquisitions, the focus remains on delivering exceptional products that meet the high standards of consumers. The integration of the Feed That Brain division is expected to provide new avenues for growth and advancement in the rapidly evolving biotech industry.

Contact Information

For more information, interested parties can reach out to Doseology Sciences Inc. via the following channels:
Email: hello@doseology.com
Website: www.doseology.com
Phone: 604.908.3095

Frequently Asked Questions

1. What does the acquisition of Feed That Brain entail?

The acquisition grants Doseology access to the Feed That Brain product line, enhancing its offerings in cognitive performance.

2. How many shares were issued to the Vendor?

The transaction involved the issuance of 175,000 common shares at a price of $1.00 per share.

3. What will be the hold period for the shares?

The issued shares will have a four-month hold period per Canadian securities regulations.

4. Who is leading Doseology Sciences Inc.?

Chris Jackson serves as the CEO of Doseology, driving the company's strategic vision.

5. How can I learn more about Doseology's projects?

For more information, individuals can visit the official Doseology website or contact the company directly via email.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.